Method for determining concentration of creatinine in a bodily fluid
US7083939B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 30, 2003 |
| Grant date | Aug 1, 2006 |
| Priority date | — |
| Expiry date | Feb 12, 2024 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/986
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method for determining concentration of creatinine in whole blood or plasma using a 1-methylhydantoinase (NMHase) catalyzed reaction, wherein the invention uses commercially available NMHase and thus eliminates prior art stabilization procedures for NMHase. Conveniently, known Trinder reagents and oxidative couplers are used for the indicator system. It has been found that by judiciously selecting the reagents used for the indicator system and/or varying the amount of enzyme NMHase that is loaded into the assay; the effect of the blank reaction can be minimized in the dynamic range of interest such that concentration of creatinine in normal and pathological levels can be measured directly without having to adjust for a blank reaction caused by bound N-methylhydantoin(NMH).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.